Trial Profile
A Retrospective Observational Study Investigating the Safety and Effectiveness of Fluciclovine (18F) (FACBC) PET Ligand in Human Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2018
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FACBC
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 24 Oct 2016 Results published in The Journal of Urology, according to a Blue Earth Diagnostics media release.
- 24 Oct 2016 Results published in a Blue Earth Diagnostics media release.